Benoit Trottier

Summary

Country: Canada

Publications

  1. doi request reprint Abacavir/lamivudine fixed-dose combination with ritonavir-boosted darunavir: a safe and efficacious regimen for HIV therapy
    Benoit Trottier
    Clinique Médicale l Actuel, Montreal, Quebec, Canada
    HIV Clin Trials 13:335-42. 2012
  2. ncbi request reprint Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks
    Benoit Trottier
    Clinique Médicale l Actuel, Montreal, Quebec, Canada
    J Acquir Immune Defic Syndr 40:413-21. 2005
  3. doi request reprint Impact of the background regimen on virologic response to etravirine: pooled 48-week analysis of DUET-1 and -2
    Benoit Trottier
    Clinique Médicale l Actuel, Montreal, Canada
    HIV Clin Trials 11:175-85. 2010
  4. pmc Adherence to Post-Exposure Prophylaxis (PEP) and Incidence of HIV Seroconversion in a Major North American Cohort
    RéJean Thomas
    Clinique Médicale l Actuel, Montreal, Quebec, Canada
    PLoS ONE 10:e0142534. 2015
  5. pmc Tolerability is more important than simplicity for treatment durability
    Benoit Trottier
    Clinical Research, Clinique Médicale l Actuel, Montreal, Canada
    J Int AIDS Soc 17:19765. 2014
  6. pmc Removing inactive NRTIs in a salvage regimen is safe, maintains virological suppression and reduces treatment costs: 96 weeks post VERITAS study
    Benoit Trottier
    Clinical Research, Clinique Médicale l Actuel, Montreal, Canada
    J Int AIDS Soc 17:19815. 2014
  7. pmc Receptor-ligand requirements for increased NK cell polyfunctional potential in slow progressors infected with HIV-1 coexpressing KIR3DL1*h/*y and HLA-B*57
    Philomena Kamya
    Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada
    J Virol 85:5949-60. 2011
  8. ncbi request reprint A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation
    Julian Falutz
    Montreal General Hospital Immuno Deficiency Treatment Centre, McGill University Health Center, Montreal, Quebec, Canada
    AIDS 19:1279-87. 2005
  9. pmc The role of extended-release niacin on immune activation and neurocognition in HIV-infected patients treated with antiretroviral therapy - CTN PT006: study protocol for a randomized controlled trial
    Bertrand Lebouché
    Chronic Viral Illness Service, Montreal Chest Institute, McGill University Health Centre, 3650 Saint Urbain St, Montreal, QC H2X 2P4, Canada
    Trials 15:390. 2014
  10. ncbi request reprint Factors associated with a decrease in the prevalence of drug resistance in newly HIV-1 infected individuals in Montreal
    Jean Pierre Routy
    Immunodeficiency Service and Division of Hematology, McGill University Health Centre, McGill University, Montreal, Quebec, Canada
    AIDS 18:2305-12. 2004

Collaborators

Detail Information

Publications11

  1. doi request reprint Abacavir/lamivudine fixed-dose combination with ritonavir-boosted darunavir: a safe and efficacious regimen for HIV therapy
    Benoit Trottier
    Clinique Médicale l Actuel, Montreal, Quebec, Canada
    HIV Clin Trials 13:335-42. 2012
    ..However, other treatment options, including the use of abacavir (ABC) and lamivudine (3TC) when used with ritonavir-boosted darunavir (DRV/r), have rarely been studied...
  2. ncbi request reprint Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks
    Benoit Trottier
    Clinique Médicale l Actuel, Montreal, Quebec, Canada
    J Acquir Immune Defic Syndr 40:413-21. 2005
    ..The T-20 Versus Optimized Background Regimen Only (TORO) studies assessed the safety and efficacy of enfuvirtide in treatment-experienced HIV-1-infected patients...
  3. doi request reprint Impact of the background regimen on virologic response to etravirine: pooled 48-week analysis of DUET-1 and -2
    Benoit Trottier
    Clinique Médicale l Actuel, Montreal, Canada
    HIV Clin Trials 11:175-85. 2010
    ..This subgroup analysis of the phase 3 DUET trials examined the impact of the background regimen on virologic response to etravirine in treatment-experienced patients...
  4. pmc Adherence to Post-Exposure Prophylaxis (PEP) and Incidence of HIV Seroconversion in a Major North American Cohort
    RéJean Thomas
    Clinique Médicale l Actuel, Montreal, Quebec, Canada
    PLoS ONE 10:e0142534. 2015
    ..There is limited evidence on the efficacy of post-exposure prophylaxis (PEP) for sexual exposures. We sought to determine the factors associated with adherence to treatment and describe the incidence of PEP failures in a Montreal clinic...
  5. pmc Tolerability is more important than simplicity for treatment durability
    Benoit Trottier
    Clinical Research, Clinique Médicale l Actuel, Montreal, Canada
    J Int AIDS Soc 17:19765. 2014
    ..Our objective was to compare the duration of first-line STRs to multi-tablet regimens...
  6. pmc Removing inactive NRTIs in a salvage regimen is safe, maintains virological suppression and reduces treatment costs: 96 weeks post VERITAS study
    Benoit Trottier
    Clinical Research, Clinique Médicale l Actuel, Montreal, Canada
    J Int AIDS Soc 17:19815. 2014
    ..Virological, immunological, clinical and financial outcomes were evaluated at an additional 96 weeks of follow-up...
  7. pmc Receptor-ligand requirements for increased NK cell polyfunctional potential in slow progressors infected with HIV-1 coexpressing KIR3DL1*h/*y and HLA-B*57
    Philomena Kamya
    Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada
    J Virol 85:5949-60. 2011
    ..The protective effect of HLA-B*57 on slow progression to AIDS and low VL may be mediated through its interaction with KIR3DL1 alleles to educate NK cells for potent activity upon stimulation...
  8. ncbi request reprint A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation
    Julian Falutz
    Montreal General Hospital Immuno Deficiency Treatment Centre, McGill University Health Center, Montreal, Quebec, Canada
    AIDS 19:1279-87. 2005
    ..To investigate the effects of TH9507, a novel growth hormone releasing factor, on abdominal fat accumulation, metabolic and safety parameters in HIV-infected patients with central fat accumulation...
  9. pmc The role of extended-release niacin on immune activation and neurocognition in HIV-infected patients treated with antiretroviral therapy - CTN PT006: study protocol for a randomized controlled trial
    Bertrand Lebouché
    Chronic Viral Illness Service, Montreal Chest Institute, McGill University Health Centre, 3650 Saint Urbain St, Montreal, QC H2X 2P4, Canada
    Trials 15:390. 2014
    ....
  10. ncbi request reprint Factors associated with a decrease in the prevalence of drug resistance in newly HIV-1 infected individuals in Montreal
    Jean Pierre Routy
    Immunodeficiency Service and Division of Hematology, McGill University Health Centre, McGill University, Montreal, Quebec, Canada
    AIDS 18:2305-12. 2004
    ..A study of chronically infected (CI) patients, who represent potential HIV-1 transmitters, was carried out in order to ascertain biological factors associated with this trend change...
  11. pmc Dendritic Cell Immunotherapy for HIV-1 Infection Using Autologous HIV-1 RNA: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
    Jeffrey M Jacobson
    Division of Infectious Diseases and HIV Medicine, Drexel University College of Medicine, Philadelphia, PA Division of Hematology and Chronic Viral Illness Service, McGill University, Montreal, Quebec, Canada Department of Epidemiology and Biostatistics, Drexel University College of Medicine, Philadelphia, PA Argostherapeutics, Durham, NC Division of Infectious Diseases, the Ottawa Hospital and the University of Ottawa, Ottawa, CA Department of Internal Medicine, University of California Davis Medical Center, Sacramento, CA Department of Medicine, Albert Einstein College of Medicine, New York, NY Clinique Medicale du Quartier Latin, Montreal, Quebec, Canada Duke University Medical Center, Durham, NC UNC HIV Cure Center and Departments of Medicine, Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC Clinique Medicale l Actuel, Montreal, Quebec, Canada and Frontier Science, Amherst, NY
    J Acquir Immune Defic Syndr 72:31-8. 2016
    ..AGS-004 amplifies translation-competent RNA molecules encoding for Gag, Rev, Vpr, and Nef from the patient's autologous virus and loads them into dendritic cells...